Weight loss pills and shakes are increasingly used across the UK to support weight management in people living with overweight or obesity. From NHS-prescribed medications such as orlistat and semaglutide to over-the-counter supplements and meal replacement programmes, the range of available options can be difficult to navigate. Understanding which products are clinically evidenced, how they are regulated by the MHRA, and when professional guidance is essential can help individuals make safer, more informed choices. This article outlines the main types of weight loss products available in the UK, what the evidence says about their effectiveness, and the key safety considerations to be aware of before starting any weight management regimen.

How Weight Loss Pills and Shakes Are Used in the UK

Weight loss pills and shakes are used across a spectrum from medically supervised NHS programmes to self-directed OTC purchases, and are intended as adjuncts to lifestyle change rather than standalone treatments.

Weight loss pills and shakes are used across the UK as part of broader efforts to manage body weight, particularly in individuals living with overweight or obesity. For context, overweight is generally defined as a BMI of 25–29.9 kg/m², and obesity as a BMI of 30 kg/m² or above. It is important to note that lower BMI thresholds apply for some ethnic groups — for example, a BMI of 23 kg/m² or above may indicate increased risk in people of South Asian, Chinese, or Black African or Caribbean heritage.

Use of these products spans a wide spectrum — from medically supervised programmes to self-directed approaches using products purchased over the counter or online. In clinical settings, weight management products are introduced alongside dietary advice, physical activity guidance, and behavioural support, rather than as standalone solutions. Pharmacological treatment is an adjunct to lifestyle change and is typically delivered within structured NHS services (see below), not as a first-line or isolated intervention.

Meal replacement shakes are commonly used to substitute one or two meals per day, reducing overall calorie intake in a structured way. Weight loss pills, depending on their type, may work by suppressing appetite, reducing fat absorption, or influencing metabolic processes. These products are not universally appropriate, and their suitability depends on an individual's overall health, medical history, and weight management goals.

The NHS recommends a gradual, sustainable approach to weight loss — typically aiming for 0.5 to 1 kg per week. NHS weight management services are organised into tiers: Tier 2 (community-based lifestyle programmes), Tier 3 (specialist multidisciplinary services, where pharmacotherapy is usually initiated), and Tier 4 (bariatric surgery for eligible individuals). Understanding how weight loss products are intended to be used, and within what clinical context, is essential before starting any weight management regimen.

When purchasing any weight loss product, it is strongly advisable to use a pharmacy registered with the General Pharmaceutical Council (GPhC). Buying from unregulated online sources carries a significant risk of receiving counterfeit, adulterated, or unlicensed products.

Types Available: Prescription, OTC, and Meal Replacement Options

UK weight loss products fall into three categories: prescription medications (orlistat, semaglutide, liraglutide), OTC options (Alli 60 mg and unregulated supplements), and meal replacement or very low-calorie diet programmes.

Weight loss products available in the UK broadly fall into three categories: prescription medications, over-the-counter (OTC) products, and meal replacement programmes.

Prescription medications currently licensed in the UK for weight management include:

• Orlistat 120 mg (Xenical) — a lipase inhibitor that reduces dietary fat absorption by approximately 30%. Per its UK Summary of Product Characteristics (SmPC), it is licensed for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above in the presence of weight-related risk factors such as type 2 diabetes or hypertension. Treatment should be discontinued if less than 5% of initial body weight has been lost after 12 weeks.

• Semaglutide (Wegovy) — a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. It is licensed by the MHRA for weight management and is recommended by NICE (Technology Appraisal TA875) for use within specialist NHS weight management services for adults with a BMI of 35 kg/m² or above (or 32.5 kg/m² or above in some ethnic groups) and at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in specific circumstances. It is important to note that Wegovy is the licensed weight-management formulation of semaglutide; the diabetes formulation (Ozempic) should not be used off-label for weight loss.

• Liraglutide (Saxenda) — another GLP-1 receptor agonist licensed for weight management. NICE Technology Appraisal TA664 defines the NHS commissioning criteria, which are more restricted than the marketing authorisation. Per the SmPC, liraglutide should be discontinued if less than 5% of initial body weight has been lost after 12 weeks at the maintenance dose of 3 mg.

NHS eligibility criteria (as defined by NICE Technology Appraisals) may differ from the broader marketing authorisation for each medicine. Patients should discuss their individual eligibility with their GP or specialist.

OTC options include a lower-dose formulation of orlistat — Alli (orlistat 60 mg) — available from pharmacies following a consultation with a pharmacist. It is indicated for adults with a BMI of 28 kg/m² or above and is used alongside a reduced-calorie, lower-fat diet. Various herbal supplements and appetite suppressants are also sold OTC, though most lack robust clinical evidence and are not regulated as medicines by the MHRA.

Meal replacement shakes and very low-calorie diets (VLCDs) — typically providing 800 kcal or fewer per day — are available through commercial programmes such as Cambridge Weight Plan. NICE guidance (NG246) acknowledges that total diet replacement programmes can be effective for short-term weight loss when used under appropriate supervision. These are distinct from general protein shakes or nutritional supplements, which are not specifically designed for weight loss.

The regulatory landscape for weight management medicines continues to evolve. Newer agents, such as tirzepatide, are under review or have recently received approval; patients and clinicians should check the MHRA, EMA, and NICE websites for the most current information.

What the Evidence Says About Safety and Effectiveness

Licensed prescription medications have the strongest evidence base; OTC supplements generally lack robust clinical data, and some botanical ingredients carry safety risks including hepatotoxicity.

The evidence base for weight loss products varies considerably depending on the type of intervention.

Licensed prescription medications have the strongest clinical evidence. Semaglutide (Wegovy) demonstrated an average weight reduction of approximately 15% of body weight in the STEP 1 and STEP 3 clinical trials (approximately 68 weeks' duration) when combined with lifestyle intervention — a significant outcome compared to placebo. Importantly, evidence from the STEP 4 extension trial indicates that much of the weight lost is regained following discontinuation, underscoring the need for long-term management planning. Orlistat has been shown to produce modest but clinically meaningful weight loss of around 3–5% more than placebo over 12 months, as supported by Cochrane systematic review evidence and NICE appraisals.

Meal replacement programmes also have a reasonable evidence base. The landmark UK DiRECT trial (The Lancet, 2018) demonstrated that a total diet replacement approach could achieve remission of type 2 diabetes in a significant proportion of participants, highlighting the potential of structured low-calorie interventions beyond simple weight loss.

In contrast, the evidence for many OTC supplements and herbal weight loss products is considerably weaker. Ingredients such as green tea extract, glucomannan, and conjugated linoleic acid (CLA) have been studied, but results are generally modest, inconsistent, or based on short-term trials with small sample sizes. The European Food Safety Authority (EFSA) has approved a limited health claim for glucomannan in the context of weight management, but only under specific conditions of use. Regulatory bodies including the MHRA have not approved most OTC supplements as medicines, meaning they are not held to the same standards of efficacy and safety. Some botanical ingredients — including high-dose green tea extract — have been associated with reports of hepatotoxicity; patients should exercise caution and seek advice before use.

It is also worth noting that long-term weight maintenance remains challenging regardless of the method used. Evidence consistently shows that combining any weight loss intervention with sustained behavioural and lifestyle changes produces the best outcomes. Products used in isolation, without addressing underlying dietary habits and physical activity, are unlikely to deliver lasting results.

MHRA and NHS Guidance on Weight Management Products

The MHRA licenses prescription weight loss medicines and warns against unlicensed online products; NICE guidance recommends pharmacotherapy only within structured NHS weight management services for eligible adults.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices available in the UK are safe, effective, and of acceptable quality. Prescription weight loss medications such as orlistat, semaglutide, and liraglutide have undergone rigorous regulatory review and hold a valid marketing authorisation in the UK.

The MHRA has issued specific warnings about unlicensed weight loss products sold online, some of which have been found to contain undeclared pharmaceutical ingredients, including stimulants and diuretics. Of particular concern, 2,4-dinitrophenol (DNP) is an illegal substance that has been sold as a weight loss product and has caused deaths in the UK; it should never be used under any circumstances. Patients are strongly advised to purchase medicines only from GPhC-registered pharmacies and to avoid unregulated online sellers.

The NHS advises that individuals seeking support with weight management should speak to their GP in the first instance. NHS weight management services are structured in tiers: Tier 2 (community lifestyle programmes), Tier 3 (specialist multidisciplinary services, where pharmacotherapy is typically initiated), and Tier 4 (bariatric surgery for eligible individuals, as defined by NICE criteria). The NHS provides access to licensed medications through appropriate clinical pathways.

NICE guidance on obesity management recommends a stepped-care approach, with lifestyle interventions forming the foundation. For pharmacological treatment:

• NICE TA875 recommends semaglutide (Wegovy) as an option within specialist NHS weight management services for eligible adults.

• NICE TA664 defines the more restricted NHS commissioning criteria for liraglutide (Saxenda).

• NICE NG246 (2023) provides the overarching framework for identification, assessment, and management of obesity, including referral pathways to Tier 3 and Tier 4 services.

NICE does not recommend the routine use of OTC supplements for weight loss, given the limited and inconsistent evidence base for most such products.

If you experience a suspected side effect from any weight loss product — whether prescription, OTC, or a supplement — you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to patients and healthcare professionals alike.

Experiencing these side effects? Our pharmacists can help you navigate them →

Potential Risks, Side Effects, and Interactions to Be Aware Of

Side effects vary by product type: orlistat causes gastrointestinal effects and drug interactions; GLP-1 agonists carry risks of pancreatitis, gallbladder disease, and perioperative aspiration; OTC supplements may contain undeclared stimulants or cause liver injury.

All weight loss products carry a potential for side effects, and these vary significantly depending on the type of product used.

Orlistat (Xenical 120 mg and Alli 60 mg) commonly causes gastrointestinal side effects, particularly when taken alongside a high-fat diet. These include:

• Oily or fatty stools

• Frequent or urgent bowel movements

• Flatulence and abdominal discomfort

Orlistat can reduce the absorption of fat-soluble vitamins (A, D, E, and K); a daily multivitamin is often recommended, taken at bedtime (i.e., at a different time to orlistat doses). Important drug interactions include: ciclosporin (reduced blood levels — avoid concurrent use or separate doses and monitor closely), warfarin (INR should be monitored closely as anticoagulant effect may be altered), levothyroxine (take at least 4 hours apart), and antiepileptic medicines (monitor for changes in seizure control). Orlistat is contraindicated in chronic malabsorption syndromes and cholestasis. Rare but serious adverse effects include severe hepatic injury and oxalate nephropathy — patients should seek medical attention promptly if they develop jaundice, dark urine, or significant abdominal pain.

Worried about interactions with other medications? Speak to one of our pharmacists →

GLP-1 receptor agonists (semaglutide/Wegovy and liraglutide/Saxenda) are associated with:

• Nausea, vomiting, and diarrhoea — particularly during dose escalation; these effects usually diminish over time

• Reduced appetite and delayed gastric emptying

• Gallbladder disease, including gallstones and cholecystitis — patients should report persistent upper abdominal pain

• Dehydration and acute kidney injury — particularly if vomiting or diarrhoea is severe; patients should maintain adequate fluid intake

• Perioperative risk: delayed gastric emptying may increase the risk of pulmonary aspiration during anaesthesia. Patients should inform their anaesthetist or surgical team that they are taking a GLP-1 receptor agonist and follow local pre-operative guidance

• Pancreatitis: patients should seek urgent medical attention if they develop severe or persistent abdominal pain

• Thyroid effects: the UK SmPCs for both semaglutide and liraglutide include a precautionary note regarding thyroid C-cell findings observed in animal studies; patients with pre-existing thyroid conditions should discuss this with their prescriber. (Note: the US prescribing information includes a boxed warning for medullary thyroid carcinoma that is not replicated in UK SmPCs.)

• Pregnancy and contraception: GLP-1 receptor agonists should not be used during pregnancy. Women of childbearing potential should use effective contraception during treatment. For semaglutide, the SmPC advises discontinuing treatment at least 2 months before a planned pregnancy, given its prolonged half-life. Patients should discuss family planning with their prescriber.

Meal replacement products, when used as part of a very low-calorie diet, may cause fatigue, headaches, dizziness, and constipation, particularly in the initial stages. They are not appropriate for pregnant or breastfeeding women, children, or individuals with certain medical conditions including eating disorders.

OTC supplements carry risks that are often underappreciated. Some products contain stimulants such as synephrine or high-dose caffeine, which may raise blood pressure and heart rate. Certain botanical ingredients — including some green tea extract preparations — have been associated with reports of liver injury. Drug interactions are also a concern; for example, some herbal products may interact with anticoagulants such as warfarin. Individuals taking any regular medication should consult a pharmacist or GP before starting any supplement.

If you suspect you are experiencing a side effect from any weight loss product, please report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

When to Speak to a GP or Pharmacist About Weight Management

Speak to your GP if your BMI meets treatment thresholds, lifestyle changes have been insufficient, or you experience side effects; a pharmacist can advise on OTC suitability and potential drug interactions.

Seeking professional advice before starting any weight loss product is strongly recommended, particularly for individuals with pre-existing health conditions or those taking regular medication. A GP can assess whether a product is appropriate, identify any contraindications, and refer to specialist services where needed.

You should speak to your GP if:

• Your BMI is 30 kg/m² or above (or above the lower threshold applicable to your ethnic group), or 27–29.9 kg/m² with a weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• You have tried lifestyle changes without achieving meaningful weight loss and wish to discuss pharmacological options or referral to an NHS Tier 3 specialist weight management service

• You are considering a very low-calorie diet or total diet replacement programme

• You experience unexplained weight loss, as this may indicate an underlying medical condition requiring investigation

• You develop side effects from a weight loss product — particularly severe or persistent abdominal pain, jaundice, palpitations, or signs of an allergic reaction

• You are planning a pregnancy and are currently taking a weight loss medicine, as some treatments require a washout period before conception

For individuals with complex obesity who have not responded to lifestyle and pharmacological interventions, referral for consideration of bariatric surgery (Tier 4) may be appropriate in line with NICE criteria — your GP can advise on eligibility and referral pathways.

Note that some medicines have specific stopping rules: for example, orlistat should be discontinued if less than 5% of initial body weight has been lost after 12 weeks; liraglutide should be stopped if less than 5% has been lost after 12 weeks at the full maintenance dose. Your prescriber will review your progress and advise accordingly.

A pharmacist can help if:

• You are considering an OTC product such as Alli (orlistat 60 mg) and want to check suitability (note: Alli is indicated for adults with a BMI of 28 kg/m² or above)

• You want to understand potential interactions between a supplement and your current medicines

• You need guidance on reputable meal replacement programmes

Seek emergency help immediately (call 999 or go to your nearest A&E) if you experience:

• Severe difficulty breathing, throat swelling, or signs of anaphylaxis

• Chest pain or palpitations

• Sudden severe abdominal pain

It is also worth noting that weight management is a long-term endeavour, and emotional and psychological factors often play a significant role. If your relationship with food or your body image is affecting your wellbeing, speak to your GP about access to psychological support or referral to a specialist eating disorder service. Weight loss pills and shakes can be a useful tool for some individuals, but they work best as part of a comprehensive, person-centred approach to health.

For lower BMI thresholds applicable to some ethnic groups, and for the most current eligibility criteria for NHS-funded treatments, please refer to NICE NG246 and the relevant NICE Technology Appraisals (TA875 for semaglutide; TA664 for liraglutide).

Frequently Asked Questions